Clinical Trials Sponsored by Verizon Wireless

Total 216 results

Verizon Wireless

Unknown

Verizon Wireless - Sarasota Memorial Hospital Converged Health Management (CHM) For Heart Failure

Heart Failure

United States
Duke University
Verizon Wireless

Completed

Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)

Peripheral Artery Disease

United States
Providence Health & Services
Verizon Wireless

Completed

Telemedicine Technology Demonstration Project for Heart Failure

Heart Failure

United States
University of Miami
Verizon Wireless

Completed

Enhanced Primary Care and Technology for Children With Chronic Disease

Obesity | Overweight | Asthma

United States
Sotera Wireless, Inc.

Withdrawn

Accuracy of Non-Invasive Blood Pressure Measurement in Adults (NIBP)

Hypertension | Hypotension

United States
Sotera Wireless, Inc.

Unknown

Assessment of PPG & PAT to Detect Upper Airway Obstruction in Patients With Obstructive Sleep Apnea

Sleep Apnea, Obstructive

United States
Sotera Wireless, Inc.

Withdrawn

Accuracy of Continuous SpO2 Measurement in Adults (SPO2)

Healthy

United States
Boston Children's Hospital
Verizon Foundation

Completed

Mobile-based Social Services Screening and Referral Tool in an Pediatric Emergency Department

Emergencies | Pediatric ALL | Mobile Applications | Social Determinants of Health | Poverty

United States
Hackensack Meridian Health
Verizon Foundation

Suspended

Effectiveness of Using Educational Modules Via Bedside Tablet in Newly Diagnosed Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
Cerimon Pharmaceuticals

Completed

Basiliximab in Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Poland, Belgium, United Kingdom, Czech Republic, Russian Federation, Slovakia, Ukraine, India
Horizon Outreach

Recruiting

Horizon Eagle Fatherhood Program

Responsible Fatherhood Programming

United States
Cerimon Pharmaceuticals

Terminated

Basiliximab Maintenance in Ulcerative Colitis

Ulcerative Colitis

United Kingdom
Horizon Therapeutics USA, Inc.

Completed

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

Thyroid Eye Disease | Chronic (Inactive) Thyroid Eye Disease

United States
Horizon Health Network

Recruiting

Carbohydrate Loading and Elderly Patients Undergoing Spine Surgery

Diet, Carbohydrate Loading

Canada
Horizon Health Network

Completed

Hand K-wire Infections in Operating Room Versus Ambulatory Setting

Hand Fracture | Infection Due to Internal Fixation Pin

Canada, Philippines
Horizon Health Network

Completed

The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery

Radiculopathy

Canada
Horizon Health Network

Completed

Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting (MIR-CABG)

Surgical Site Infections

Canada
Cerimon Pharmaceuticals
PPD

Completed

Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain (SUPPORT 2)

Acute Pain | Ankle Sprain

United States
Horizon Therapeutics USA, Inc.

Terminated

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis

United States
Virion Therapeutics

Recruiting

Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

Chronic Hepatitis B

Hong Kong, New Zealand
Horizon Health Network

Recruiting

The CHARM Study-Coordinating Transitions From Hospital for Older Adults With Fractures

Frailty | Aging | Fracture

Canada
Horizon Health Network

Unknown

Effects of Intra-Operative Ropivaciane Epidural Injection on Post-Operative Outcomes Following Elective Lumbar Fusion

Pain, Postoperative
Cerimon Pharmaceuticals
PPD

Terminated

Diclofenac Patch for Treatment of Mild to Moderate Ankle Sprain

Ankle Sprain

United States
Cerimon Pharmaceuticals
PPD

Completed

Diclofenac Patch for Treatment of Mild to Moderate Tendonitis or Bursitis

Rotator Cuff Tendonitis | Bicipital Tendonitis | Subdeltoid Bursitis of the Shoulder | Subacromial Bursitis of the Shoulder | Medial Epicondylitis of the Elbow | Lateral Epicondylitis of the Elbow | DeQuervain's Tenosynovitis of the Wrist

United States
Horizon Health Network

Active, not recruiting

Multiple Myeloma Molecular Monitoring Study (M4)

Multiple Myeloma

Canada
Horizon Health Network

Completed

Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization

Methicillin-resistant Staphylococcus Aureus

Canada
Cerimon Pharmaceuticals
PPD

Terminated

The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis (BSX-003)

Non-infectious Uveitis

United States
Cerimon Pharmaceuticals
PPD

Completed

Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)

Acute Pain | Soft Tissue Injury

United States
Cerimon Pharmaceuticals
PPD

Completed

Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion (WIND)

Acute Pain

United States
Horizon Therapeutics, LLC

Terminated

Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs) (THRIVE)

Urea Cycle Disorder

United States
Horizon Therapeutics, LLC

Completed

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Urea Cycle Disorder

United States, Canada
Horizon Therapeutics, LLC

Completed

To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)

Urea Cycle Disorders

United States, Canada
Horizon Therapeutics, LLC

Completed

Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)

Urea Cycle Disorder

United States, Spain, Italy, Switzerland
Horizon Therapeutics Ireland DAC

Not yet recruiting

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (N-MOmentum LT)

Neuromyelitis Optica Spectrum Disorder
Horizon Therapeutics Ireland DAC

Recruiting

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder

United Kingdom, Brazil, Serbia, United States, Canada, France, Poland, Spain, Sweden, Argentina, Netherlands
Children's Hospital Medical Center, Cincinnati
Verizon Foundation; Luther Foundation

Completed

Improving Asthma Care by Partnering With School Nurses to Bring Asthma Care Into the Inner-City Schools (AFS4)

Asthma

United States
Horizon Pharma USA, Inc.

Completed

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

Cystinosis

United States, Brazil
Horizon Pharma USA, Inc.

Completed

A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Horizon Pharma USA, Inc.

Completed

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

Aldehyde Dehydrogenase-2 (ALDH2) Deficiency

United States
Horizon Therapeutics Ireland DAC

Not yet recruiting

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

Sjogren's Syndrome
Horizon Therapeutics Ireland DAC

Recruiting

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Gout

United States
Horizon Therapeutics Ireland DAC

Recruiting

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Sjogren's Syndrome

United States
Horizon Therapeutics Ireland DAC

Recruiting

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

Pregnancy Related | Neuromyelitis Optica Spectrum Disorder

United States
Horizon Therapeutics Ireland DAC

Completed

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

Uncontrolled Gout

United States
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (OPTIC)

Thyroid Eye Disease | Graves' Orbitopathy

United States, Italy, Germany
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X)

Thyroid Eye Disease

Italy, United States, Germany
Horizon Pharma USA, Inc.

Approved for marketing

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (EAP)

Thyroid Eye Disease | Graves' Orbitopathy

United States
Horizon Pharma Rheumatology LLC

Completed

Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout (EyesOnGOUT)

Refractory Chronic Gout

United States
Horizon Pharma USA, Inc.

Completed

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Cystinosis

France, United States, United Kingdom, Belgium, Italy, Netherlands
Horizon Pharma USA, Inc.

Completed

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Cystinosis

France, United States, Netherlands

3

Subscribe